Our Pricing

Understanding Mounjaro: How It Works and Side Effects

Understanding Mounjaro side effects and how it works UK is essential before starting treatment. As a dual GIP/GLP-1 receptor agonist, Mounjaro (tirzepatide) represents a significant advancement in weight management, but like all prescription medications, it requires proper clinical oversight and awareness of potential side effects. Our UK-registered clinical team provides comprehensive assessments to determine if Mounjaro is suitable for your individual health profile.

How Mounjaro Works: The Science Behind Tirzepatide

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide simultaneously activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, creating a synergistic effect on appetite regulation and metabolic function.

This dual mechanism works by slowing gastric emptying, reducing appetite signals to the brain, and improving insulin sensitivity [1]. In the landmark SURMOUNT-1 trial, participants achieved an average body weight reduction of 22.5% at the 15mg maintenance dose over 72 weeks — significantly higher than previous GLP-1-only treatments [2]. The medication is administered as a once-weekly subcutaneous injection, with doses gradually increased from 2.5mg to a maintenance dose of 5mg, 10mg, or 15mg depending on individual response and tolerability.

Clinical data demonstrates that tirzepatide's dual-receptor activation produces superior glycaemic control and weight reduction compared to selective GLP-1 agonists, though individual results vary and all treatment requires ongoing clinical supervision [1][2].

Common Mounjaro Side Effects: What to Expect

The most frequently reported Mounjaro side effects are gastrointestinal in nature, particularly during the initial titration phase. In clinical trials, nausea affected approximately 20-30% of participants, typically mild to moderate in severity and diminishing over time [3]. Other common gastrointestinal effects include diarrhoea, vomiting, constipation, and abdominal discomfort.

These side effects are generally most pronounced during dose escalation and often improve as your body adjusts to the medication [3]. Starting at the lowest dose (2.5mg) and gradually increasing every four weeks allows your system to adapt, significantly reducing the intensity of gastrointestinal symptoms. Most patients find these effects manageable and temporary, resolving within the first 4-8 weeks of treatment.

Less common but important side effects include injection site reactions (redness, itching, or swelling), fatigue, and changes in taste. Hypoglycaemia is rare when Mounjaro is used alone but may occur if combined with other diabetes medications [3]. Our clinical team provides detailed guidance on managing side effects and adjusting your treatment plan if necessary.

Managing Gastrointestinal Side Effects

Practical strategies can significantly reduce gastrointestinal discomfort during Mounjaro treatment. Eating smaller, more frequent meals rather than large portions helps minimise nausea and bloating. Avoiding high-fat, greasy, or spicy foods during the first few weeks can also reduce digestive upset. Staying well-hydrated is essential, particularly if you experience vomiting or diarrhoea.

If side effects become troublesome, your prescriber may recommend remaining at your current dose for an additional week or two before increasing, or adjusting the titration schedule to better suit your individual tolerance. Never adjust your dose without consulting your UK prescriber first.

Serious Side Effects and When to Seek Medical Attention

While rare, certain serious side effects require immediate medical attention. Symptoms of pancreatitis — severe persistent abdominal pain that may radiate to the back, often accompanied by nausea and vomiting — should prompt urgent medical review [4]. Clinical trials showed pancreatitis occurred in fewer than 1% of participants, but awareness is crucial.

Allergic reactions, though uncommon, can include rash, itching, swelling of the face or throat, difficulty breathing, or rapid heartbeat. Seek emergency care immediately if you experience these symptoms [4]. Signs of thyroid tumours — a lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath — also warrant prompt medical evaluation, though the clinical relevance to humans remains under investigation.

Gallbladder problems, including gallstones and cholecystitis, occurred more frequently in tirzepatide-treated patients in clinical trials, particularly during rapid weight loss [4]. Symptoms include upper abdominal pain, fever, yellowing of skin or eyes, and clay-coloured stools. Changes in vision, severe or persistent stomach pain, or signs of kidney problems (reduced urination, swelling in legs or feet) should be reported to your healthcare provider immediately.

Mounjaro Side Effects vs Other Weight Loss Treatments

When comparing side effect profiles across weight loss medications, tirzepatide demonstrates a similar gastrointestinal side effect pattern to other GLP-1 receptor agonists, though the dual mechanism may influence both efficacy and tolerability. In head-to-head trials, Mounjaro showed comparable rates of nausea and vomiting to semaglutide-based treatments, with some studies suggesting slightly higher gastrointestinal effects at equivalent weight loss levels [5].

The key difference lies in the magnitude of weight reduction achieved — Mounjaro's superior efficacy in clinical trials means patients may reach their weight goals at lower relative doses, potentially reducing the cumulative side effect burden over time [2][5]. However, individual tolerance varies significantly, and some patients may find alternative treatments better suited to their physiology.

Orlistat-based treatments present an entirely different side effect profile, primarily causing gastrointestinal effects related to fat malabsorption rather than appetite suppression. The choice between injectable GLP-1 treatments and oral alternatives depends on your medical history, lifestyle preferences, and how you respond to initial treatment under clinical supervision.

Choosing Between Mounjaro and Alternative Treatments

Your UK prescriber will assess multiple factors when recommending a weight loss treatment, including your BMI, existing medical conditions, previous treatment responses, and personal preferences regarding injection frequency versus oral medications. Patients with a history of gastrointestinal disorders may require more cautious dose titration or alternative treatment options.

At Cured Pharmacy, our clinical team conducts thorough assessments to match you with the most appropriate treatment. This includes reviewing your complete medical history, current medications, and any contraindications specific to GLP-1 receptor agonists. All prescription treatments require this clinical evaluation before dispensing.

Who Should Not Take Mounjaro: Contraindications and Precautions

Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [6]. Animal studies demonstrated thyroid C-cell tumours at clinically relevant exposures, though human relevance remains uncertain. Your prescriber will screen for these conditions during your clinical assessment.

The medication is not recommended during pregnancy or breastfeeding, as weight loss offers no benefit during pregnancy and animal studies showed potential foetal harm [6]. Women of childbearing potential should use effective contraception during treatment and for at least four weeks after discontinuation. If you become pregnant while taking Mounjaro, contact your prescriber immediately to discuss alternative management.

Caution is required in patients with severe gastrointestinal disease, including gastroparesis or inflammatory bowel disease, as tirzepatide slows gastric emptying and may exacerbate these conditions [6]. Patients with a history of pancreatitis, severe renal impairment, or diabetic retinopathy should be monitored closely. Your UK prescriber will evaluate these risk factors during your consultation to ensure safe, appropriate treatment.

Starting Mounjaro Safely: What to Expect from Your Clinical Assessment

Before prescribing Mounjaro, our UK-registered clinical team conducts a comprehensive assessment covering your medical history, current medications, weight loss goals, and any contraindications. This typically takes under three minutes to complete online but ensures treatment safety and appropriateness. Your prescriber will calculate your BMI, review previous weight loss attempts, and assess for conditions that may affect treatment suitability.

The standard titration schedule begins at 2.5mg once weekly for four weeks, increasing to 5mg for the next four weeks, then potentially to 10mg or 15mg based on your response and tolerability [1]. This gradual escalation minimises side effects while allowing your body to adjust. Your prescriber will provide detailed injection technique guidance, including rotation of injection sites (abdomen, thigh, or upper arm) to reduce local reactions.

Ongoing monitoring is essential throughout treatment. Your prescriber may recommend follow-up assessments at regular intervals to evaluate weight loss progress, side effect management, and any necessary dose adjustments. At Cured Pharmacy, genuine UK-licensed Mounjaro is available from £135.00 with transparent pricing provided before your consultation. All treatments are dispensed discreetly by our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

Maximising Treatment Success

Mounjaro works most effectively when combined with lifestyle modifications including a reduced-calorie diet and increased physical activity. Clinical trials demonstrating significant weight loss included dietary counselling and exercise recommendations as part of the treatment protocol [2]. Your prescriber can provide guidance on sustainable lifestyle changes to optimise your results.

Consistency is crucial — administer your injection on the same day each week, though the time of day can vary. If you miss a dose and it's within four days of your scheduled injection, take it as soon as possible. If more than four days have passed, skip the missed dose and resume your normal schedule. Never double up on doses to compensate for missed injections.

Scientific References

1. Frias, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
2. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
3. Dahl, D., et al. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA, 327(6), 534–545. https://doi.org/10.1001/jama.2022.0078
4. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
5. Garvey, W. T., et al. (2022). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X
6. European Medicines Agency. (2022). Mounjaro: EPAR – Product Information. EMA. https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine and can only be supplied following a consultation with a UK prescriber who will assess your suitability for treatment.